Join the Oncology Brothers, for an insightful Clinical Insights discussion on treatment strategies for hormone receptor-positive metastatic breast cancer, with a focus on biomarker testing and targeted therapies. We were joined by the breast cancer experts Dr. Alia Nazarullah, Dr. Virginia Kaklamani, Dr. William Gradishar, and Dr. Kevin Kalinsky.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9...
Apple Podcast: https://podcasts.apple.com/us/podcast...

Follow us on social media:
•⁠  ⁠X/Twitter: https://x.com/oncbrothers
•⁠  ⁠Instagram: Instagram: oncbrothers
•⁠  Website: https://oncbrothers.com/

In this episode, the experts discussed:

• The workflow for biomarker and mutation testing in metastatic breast cancer
• The complementary roles of tissue-based and liquid biopsy testing
• The clinical significance of PIK3CA and ESR1 mutations
• The evolving role of next-generation sequencing (NGS) in treatment selection
• New targeted therapies, including inavolisib, and how biomarker results can guide treatment decisions
• Strategies for managing treatment-related adverse effects
• Practical clinical cases illustrating the challenges of treatment selection in metastatic breast cancer

The discussion highlighted how molecular testing is increasingly being integrated into clinical decision-making for metastatic breast cancer and how emerging targeted therapies are expanding treatment options for patients with specific tumor biomarkers.

Whether you're a medical oncologist, pathologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in breast cancer care, this episode provides practical insights into biomarker-driven treatment strategies and the rapidly evolving metastatic breast cancer landscape.

If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments.

#BreastCancer #MetastaticBreastCancer #PIK3CA #ESR1 #OncologyBrothers